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Abstract
Background
For women suffering from an antepartum mental disorder (AMD), there is lack of evidence-
based treatment algorithms due to the complicated risk-benefit analysis for both mother and
unborn child. We aimed to provide a comprehensive overview of pharmacological and non-
pharmacological interventions to treat AMD and performed a meta-analysis of the estimated
treatment effect on the psychiatric symptoms during pregnancy.
Methods
MedLine, PsycINFO and Embase databases were searched by two independent reviewers
for clinical trials with a control condition on treatment of women with AMD, i.e. major depres-
sive (MDD), anxiety, psychotic, eating, somatoform and personality disorders. We invento-
ried the effect of the treatment, i.e. decrease of psychiatric symptoms at the end of the
treatment or postpartum. We adhered to the PRISMA-protocol.
Findings
Twenty-nine trials were found involving 2779 patients. Trials studied patients with depres-
sive disorders (k = 28), and anxiety disorders (k = 1). No pharmacological trials were
detected. A form of psychotherapy, like Cognitive Behavioural Therapy (g = -0.61; 95%CI:-
0.73 to -0.49, I2 = 0%; k = 7) or Interpersonal Psychotherapy (g = -0.67; 95%CI:-1.27 to
-0.07; I2 = 79%; k = 4), holds robust benefit for pregnant women with MDD. Body-oriented
interventions (g = -0.43; 95%CI:-0.61 to -0.25; I2 = 17%; k = 7) and acupuncture (g = -0.43;
95%CI:-0.80 to -0.06; I2 = 0%; k = 2) showed medium sized reduction of depressive symp-
toms. Bright light therapy (g = -0.59; 95%CI:-1.25 to 0.06; I2 = 0%; k = 2), and food supple-
ments (g = -0.51; 95%CI:-1.02 to 0.01; I2 = 20%; k = 3) did not show significant treatment
effects. One study was found on Integrative Collaborative Care.
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Conclusions
This meta-analysis found a robust moderate treatment effect of CBT for MDD during preg-
nancy, and to a lesser extent for IPT. As an alternative, positive results were found for body-
oriented interventions and acupuncture. No evidence was found for bright light therapy and
food supplements. Only non-pharmacological trials on women with MDD were found.
Research on a wider range of AMD is needed.
Introduction
Antepartum mental disorders (AMDs) are a major cause of disability among women during
the perinatal period, and may have consequences for children’s (intra-uterine) growth and
development [1, 2]. To date, most reviews and treatments for antepartum mental disorders
focussed on depression [3, 4] while a broader range of mental disorders is prevalent during
pregnancy and psychiatric symptoms may overlap. The heterogeneity of patients is reflected
by estimates from the National Epidemiologic Survey among 43094 American women, show-
ing that the 12-month prevalence of the full range of AMDs did not differ from outside of
pregnancy [5], nor resulting in lower rates [6, 7]. According to DSM-IV criteria, most preva-
lent AMDs were major depressive disorder (MDD), anxiety disorder and psychotic disorder in
pregnant women. Prevalence rates of a mental disorder during pregnancy was 25.3%; almost
equivalent among postpartum women (27.5%) and non-pregnant women (30.1%) [5].
In a hospital setting, the prevalence of AMDs is similar to cohort studies and additionally a
high number of co-morbid mental disorders is found [8–11], e.g. several studies showed that
24.0% had2 or more co-morbid disorders and 5.0% had3 or more co-morbid mental dis-
orders. To clinicians, a pregnant woman can present with a range of psychiatric and somatic
symptoms, which sometimes overlap with typical “pregnancy complaints”. For diagnostic
and therapeutic purposes, it is important to verify whether a patient dysfunctions in all life
domains and to determine the mental disorder(s) according to the DSM-IV criteria. For
MDD, DSM-V criteria remained the same and our outcomes can be extrapolated to the cur-
rent situation. In consultation with the patient, a tailored treatment should be promptly
offered, because of the on-going adverse influence of AMDs on the gestation and the increased
risk to harmful health behaviours of mother, e.g. smoking, substance use, poor nutrition and
avoidance of obstetric care [12, 13]. It has been hypothesized that most relevant effects of
AMDs on the foetus take place during mid-gestation and are associated with adverse obstetric
outcomes, including preterm delivery, low birth weight, hypertension and preeclampsia [14–
17]. To protect the foetus, it is necessary to weigh the potential benefit of treating the mother’s
AMD with psychotropic medication against the adverse effects of not treating or relapsing of
AMD. There are no suitable data available to guide evidence-based decisions on pharmacolog-
ical treatment of AMD during pregnancy. Selective serotonin reuptake inhibitors (SSRIs) are
the most frequently used pharmacological treatment in pregnant women with MDD, with an
estimated 2–3% of women in Europe. There a no studies on (dis)continuation of SSRIs during
pregnancy, only two naturalistic studies investigated the preventive effect of SSRI’s for MDD
during pregnancy and the results are equivocal [18, 19]. It poses pregnant women and clini-
cians for a dilemma, what is best for foetus and mother?
From a patient and clinician perspective, there is need to explore evidence for pharmaco-
therapy and also alternative non-pharmacological treatments for AMDs. In case of depressive
disorders, several alternative treatment algorithms in non-pregnant women are shown to be
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effective [20] and Dennis et al. systematically reviewed these interventions in antenatal depres-
sion [21–23]. The authors concluded that for antenatal depression the evidence is too incon-
clusive to make any recommendations for depression-specific acupuncture, maternal massage,
bright light therapy, and omega-3 fatty acids [21]. Various treatments for depression during
pregnancy have been systematically reviewed [24–34], however, it remains unclear which non-
pharmacological treatment clinicians should offer to pregnant patients with (co-morbid) men-
tal disorders other than depression.
For clinicians it is important to know all available alternative treatments, next to pharmaco-
therapy, that he/she can offer to a patient with AMD. Our systematic review aimed to provide
an overview of randomized or open intervention trials with a control condition that evaluated
pharmacological and all non-pharmacological interventions for AMD. Subsequently, the aim
of our meta-analysis is to provide an estimation of the overall effect size of a decrease of psychi-
atric symptoms at the end of treatment or postpartum, for each categorized intervention per
mental disorder.
Materials and methods
Eligibility criteria
To be selected for inclusion for our review, a trial was required to meet the following criteria:
1. Type of participants. We considered trials that studied pregnant women with a
diagnosed mental disorder, with a focus on the following mental disorders and grouped in 7
categories: 1) depressive disorder (MDD, dysthymic disorder); 2) anxiety disorder, e.g. agora-
phobia, obsessive-compulsive disorder, panic disorder, phobic disorder, stress disorder, post-
traumatic stress disorder; 3) eating disorder, e.g. anorexia nervosa, binge-eating, bulimia
nervosa; 4) adjustment disorder; 5) somatoform disorder; 6) schizophrenia and other disorders
with psychotics features, e.g. bipolar disorder, or 7) personality disorder. We decided to
exclude addiction or any substance-use related disorders, e.g. nicotine-addicts or heroin users.
Studies focussing on a population with psychosocial risk factors but without a diagnosed men-
tal disorder were excluded. A prerequisite was that the AMD was diagnosed by means of a
(semi-structured) psychiatric interview during pregnancy, e.g. SCID, Mini International Neu-
ropsychiatric Interview (MINI), Composite International Diagnostic Interview (CIDI), Clini-
cal Interview Schedule-Revised (CIS-R) for ICD-10 criteria or Diagnostic Interview Schedule
(DIS), and not using screening instruments.
2. Type of treatment. We considered all available pharmacological treatments for AMD,
including antidepressants, mood stabilizers, antipsychotics, anxiolytics/tranquilizers and neu-
roleptics. Also all non-pharmacological interventions for the treatment of AMD were taken
into account, including all psychological, body-oriented therapies or other alternative forms of
treatment, or combination of these interventions. We included trials that evaluated interven-
tions, which had the primary aim to treat the mental disorder present during pregnancy. Inter-
ventions with the focus to prevent–or to treat risk factors for–postpartum psychopathology
were excluded.
3. Type of outcome measures. We included all trials that were performed during preg-
nancy and evaluated the effect of the intervention at the end of the treatment period or closest
to delivery in the postpartum period. We inventoried the effect of the treatment on the mental
disorder of the mother, i.e. decrease of psychiatric symptoms at the end of treatment or post-
partum closest to the delivery.
4. Types of trials. We included all studies with a randomized-controlled (RCT) or open
trial design and were published in a peer-reviewed journal. For reasons of validity and quality,
we decided to focus only on trials with a control condition and excluded abstracts, case-series
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and case reports. No language, publication date or publication status restrictions were
imposed.
Search strategy, data abstraction and synthesis for systematic review
Trials were identified by searching electronic databases, scanning reference lists of articles and
consultations with experts in the field. MedLine, PsychInfo and Embase were searched from
their inception to June 2016 using combinations of the following terms: Pregnancy, Mental dis-
orders, Treatment (see Fig 1 for details and flowchart). To identify other published or unpub-
lished trials, Clinical Trial Databases were searched (clinicaltrial.gov, The ICTRP Search
Portal). The last search was run on June 2th 2016. Two reviewers (LR and AK) independently
screened all titles and abstracts, excluded protocols and reviews and assessed full-text articles
for eligibility. Disagreement between reviewers was resolved by an independent psychiatrist
(MLvdB). Results are reported according to the PRISMA-protocol [35], but there was no
review protocol (see S4 Table). We assessed inter-rater agreement by kappa statistic using
GraphPad Software. A kappa value of 0.61–0.80 reflects substantial, and a kappa-value of 0.81–
1.00 (almost) perfect agreement [36]. Details related to the design of the trial, the participants
Fig 1. Flow diagram of the review selection procedure, adhered to the PRISMA statement.
https://doi.org/10.1371/journal.pone.0173397.g001
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(mental disorder definition and sample size), the description of the treatment and control con-
dition and the outcomes of the trial were extracted from the articles and reported in S1 Table.
Most trials used multiple outcomes measures and our interest was to include the outcome
measure that operationalized the clinical psychiatric symptoms best, i.e. preference for the
Edinburgh (Postnatal) Depression Scale (EDS) which is validated for the use of assessment of
depressive symptoms during pregnancy [37]. Our preference was to use the outcome data
from the Intention To Treat analysis (ITT), and otherwise data from the per protocol analysis.
In case the trial design, procedure or mental health outcomes were reported in an unusual or
inconclusive format, the corresponding author of the trial was requested for additional in-
formation. Five corresponding authors were contacted and four authors gave the additional
information. In situations when multiple articles were drawn from the same trial, the most
complete dataset was reported in detail. In case of multiple interventions, both interventions
were reviewed, but in case of multiple control conditions only the primary control condition
was reported. Pilots or feasibility trials are only mentioned briefly. Subsequently, per subgroup
of mental disorders (as described above) the studied interventions and their effect on the men-
tal disorder at the end of therapy or trial, preferably the time point closest to the delivery is
presented.
Risk of bias in individual trials and across trials
The reviewers independently rated the risk of bias for each trial according to the Cochrane
Risk of Bias Tool and reported randomization procedure, allocation concealment, blinding
procedures and selective reporting in S3 Table [38, 39]. Publication bias was visually assessed
with a funnel plot and formally with Egger’s test, to see if the effect decreased with increasing
sample size [40]. These plots should be shaped like a funnel if no publication bias is present.
However, since smaller or non-significant trials are less likely to be published, trials in the bot-
tom left-hand corner of the plot are often omitted.
Procedure for meta-analysis
For our meta-analysis, we used the same search strategy as mentioned before and included
only randomized controlled trial designs. We excluded open trials. We calculated pooled esti-
mates using bias corrected standardized mean estimates, i.e. Hedges’ g, with 95% confidence
intervals between the intervention group and the control group at the end of the trial or post-
partum closest to the delivery. Hedges’ g corrects for the differences in variances resulting
from the inclusion of trials with varying sample sizes [41]. The magnitude of Hedges’ g can be
interpreted as small (0.20), moderate (0.50), or large (0.80) in line with Cohen’s d [42]. Pooling
was performed per type of intervention and per category of mental disorder over a minimum
of two trials. Results for each subgroup of intervention are plotted in a forest plot. Random-
effects analysis were used to estimate an overall treatment effect since it produces a more reli-
able estimate than fixed effect analysis in case of substantial heterogeneity. Cochran’s Q-test,
I2, and T2 statistics were used to quantify heterogeneity across trials. I2 >40% was considered
as substantial heterogeneity. Heterogeneity was further explored by conducting sensitivity
analyses. For this aim, we calculated the overall treatment effect using both fixed and random
effects modelling and evaluated the impact of the modelling procedure on the overall treatment
effect [43]. Additionally, we created subgroups of trials based on 1) modus of intervention
(group-based vs. individual therapy), 2) timing of outcome assessment (end of therapy vs. in the
postpartum period), 3) randomization, i.e. secure vs. unknown, 4) allocation concealment
(secure vs. unknown/insecure), 5) attrition (less vs. more than 20%), 6) overall study quality
(unbiased, unknown/partially biased vs. biased), and 7) outcome measure (questionnaire used),
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and we evaluated the impact of these moderator variables on the overall treatment effect.
Finally, we assessed the influence of the age of the patient as a continuous variable on treatment
effect using random effects meta-regression analysis. Standardized effect sizes were calculated
using Comprehensive Meta-Analysis (CMA) [44]. Further statistical analyses were performed
using the “Metan package” in Stata 13 [45, 46].
Results
Using our search strategy, we identified 7021 articles (see Fig 1 for a flow diagram). After
reviewing the title and abstract, 63 articles were assessed for eligibility and 37 articles did not
meet the inclusion criteria. We included 27 articles reporting a clinical trial with a control con-
dition evaluating a treatment for AMD. After cross checking the references, we added 2 rele-
vant articles (A10, A18), thus we included 29 articles in our systematic review. Inter-rater
reliability was very good (raw inter-rater agreement = 94%; κ = 0.87). All 29 articles were pub-
lished in English between 1997 and 2015 (see S1 Table for a summary of all included articles).
A reference list of all included articles is presented in S2 Table. Together the articles described
28 unique studies; Burns et al. (A2) and Pearson et al. (A21) published on the same study
cohort. Collectively there were a total of 2779 participants in the trials. Almost all participants
were diagnosed with a depressive disorder (k = 28) and, to a lesser extent diagnosed with an
anxiety disorder (k = 1). No trials were detected with participants diagnosed with AMDs, psy-
chotic disorder, eating disorder, somatoform disorder or personality disorders. Included trials
described the effects of a variety of different interventions, e.g. Cognitive Behavioural Therapy
(CBT), Inter Personal Therapy (IPT), bright light therapy, body-oriented interventions, acu-
puncture, food supplements and Integrative Collaborative Care (ICC). The treatment period
ranged from 2 to 16 weeks and number of sessions varied between 2 to 32 sessions. Assessment
of outcome differed in timing, e.g. end of treatment period (k = 25) or postpartum period
(k = 4), and type of questionnaire frequently used were EPDS (k = 9), CES-D (k = 7) and BDI
(k = 4). The majority of the trials randomly allocated participants to an intervention or control
condition (k = 27), except for two trials with an open design. In the following paragraphs, the
results of the different interventions per diagnostic subgroup are described.
Depressive disorder
In general, the results from 28 unique trials focusing on the treatment of a depressive disorder
in pregnant women indicated beneficial effects in relation to a decrease of depressive symp-
toms at the end of treatment or in the postpartum period. These trials included participants
that fulfilled the criteria for MDD according to DSM-IV or ICD-10 criteria. Participants were
diagnosed with the SCID (k = 16), MINI (k = 3), DIS (k = 2), CIS-R (k = 2) or other clinical
(semi-structured) psychiatric interview (k = 5), often combined with a screening instrument.
The majority of the studies were conducted in a Western country (Australia, Sweden, Switzer-
land, UK, USA) and three trials were conducted in a low-resource country (Pakistan, Korea
and Taiwan). The majority of the sample sizes of the included trials were small, varying from
10 to 903 participants and covered in total 2703 participants. Except for one open trial, all trials
were (partly) randomized controlled trials.
In total, 8 trials evaluated CBT, 4 trials evaluated IPT, 3 trials examined the use of bright
light therapy, 7 trials were on body-oriented therapies, 2 trials on acupuncture, 3 trials on food
supplements and one trial on ICC. Participants were individually exposed to the intervention
(k = 21) or the treatment was delivered to a group (k = 7). Reduction of depressive symptoms
was expressed in scores on the EPDS (k = 9), CES-D (k = 7), BDI (k = 4), HDRS (k = 3),
Treatment of mental disorders during pregnancy
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SIGH-SAD (k = 3), CIS-R (k = 2), SCL-20 (k = 1) at the end of treatment (k = 23) or postpar-
tum (k = 3).
Cognitive behavioural therapy (CBT). Austin et al. conducted one of the first large RCTs
to demonstrate the superiority of CBT over a booklet and provided weekly 2-hour CBT group
sessions for 6 weeks (A1). Per protocol analyses showed that both groups symptomatically
improved over time but there was no difference between the two groups. Cho et al. conducted
a pilot randomized controlled trial to compare CBT with psycho-education with twenty-seven
depressed patients. The intervention group received 9 sessions of individual CBT and had sig-
nificantly lower rates of depression one month after childbirth (A3). In a low-resource setting,
Rahman et al. conducted a large cluster-randomized controlled trial and trained community
health workers to provide a CBT-like intervention at home. Although the primary outcome
was infant weight and height at 6 months postpartum, less mothers met criteria for major
depression in the intervention group than in the control group (OR 0.22 95%CI: 0.14 to 0.36,
p<0.001) (A22). Also in another setting, Hayden studied pregnant women with diabetes and
with depression (n = 34) and without depression (n = 68), but CBT had no beneficial effect
over supportive counseling for both groups (A14). More recent, Burns et al. and Pearson et al.
investigated CBT in a pilot RCT and randomized 36 British women who received up to 12 ses-
sions of individual CBT (A2,A21). At 15 weeks post-randomization (linked to a gestational age
of approx. 29 weeks), there were more women in the intervention group who did not met
ICD-10 criteria for depression any more than in the control group (68.7% vs. 38.5%) and Pear-
son et al. suggested that the attentional biases of women might improve after CBT. In a pilot
RCT, O’Mahen et al. showed that CBT is also a feasible and acceptable treatment for low-
income, racial minority women with MDD, however depression scores did not significant dif-
fer between the intervention and treatment as usual group (A19). Milgrom et al. showed prom-
ising results of an adapted version of a postnatal CBT program, containing 8 antepartum
sessions and also reports infant outcomes at 9 months, however post-treatment the depression
scores were not significant better for the intervention group (A29).
Interpersonal Psychotherapy (IPT). Spinelli and colleagues were the first to compare a
16-week IPT intervention with parent education matched in time and intensity (A24)[47]. The
majority of women were low-income Spanish speaking immigrants, and patients who received
IPT had a significant >50% improvement in their mood symptoms. This trial was replicated in
2013 and showed equal benefits of both interventions (A25). Grote et al. reduced the number of
sessions from 16 to 8 (brief-IPT) and still a significant larger proportion (95%) of the women in
the intervention group no longer met the criteria for MDD compared to the enhanced usual
care (58%) at 3 months postpartum (A13). Field et al. studied IPT in a group of women with
dysthymia or major depression and after 12 sessions there was no difference in mood symptoms
between the intervention and the control peer-support group (A6).
Bright light therapy. Three trials have examined the use of bright light therapy for the
treatment of antepartum depression. Oren et al. exposed 16 patients for 3 weeks to active
bright light in an ABA-design and SIGH-SAD scores improved by 49% from baseline (A20).
Withdrawal of bright light treatment was associated with an increase of depressive symptoms.
Epperson and colleagues found no significant benefit of bright light over placebo during a
5-week RCT (A4). However, in the extended 10-week trial, active bright light with 20,000 lux
had a significant treatment effect compared to 500-lux dim light (effect size 0.43). Wirz-Justice
et al. reported a significant difference on HDRS and SIGH-ADS (MD = -5.00, 95%CI:-10.00 to
0.00) scores comparing active (7000 lux) to placebo (70 lux) light therapy after 5 weeks of treat-
ment (A28).
Body-oriented interventions. Field et al. studied extensively alternative antepartum inter-
ventions for depression (A5-A11). Massage by a significant other, compared to standard care
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significantly decreased the number of women with depressive symptomatology on the Center
for Epidemiological Studies Depression Scale (CES-D) immediately post-treatment in a small
(n = 47, MD = -4.9) (A11) and bigger sample (n = 149, MD = -6.7, 95%CI:-9.8 to -3.6) (A9).
Field et al. studied also group-IPT in pregnant women and added 6 sessions of massage ther-
apy for the intervention group (A5). The group that received both interventions, showed a
greater decrease in depression and anxiety scores. Recently these authors compared yoga or
massage therapy twice weekly (A10), tai chi/yoga therapy (A8) and weekly yoga to standard
antepartum care for 12 weeks (A7). These three trials showed a significant greater decrease of
depression and anxiety scores in the intervention groups compared to the control groups.
Uebelacker compared group yoga with a mom-bay wellness workshop and found no difference
in depression scores (A27).
Acupuncture
Two trials examined the role of acupuncture, Manber and colleagues studied depression-spe-
cific acupuncture in comparison with non-specific acupuncture and massage therapy (A16-
A17). In a small sample in 2004, there were no differences in pregnant women diagnosed with
clinical depression after treatment nor at 10 weeks postpartum (A16). A new sample of 150
patients in 2010 showed that women who received acupuncture specific for depression experi-
enced a greater reduction of HDRS-rates, compared with the combined controls or control
acupuncture after 8 weeks of treatment (A17).
Food supplements
Three trials have explored the potential value of food supplements. For example, Freeman per-
formed a randomized double blind placebo controlled trial to compare the use of omega-3 fatty
acids to placebo, with supportive psychotherapy provided to all patients (A12) and studied ther-
apy adherence [48]. Both groups experienced a significant improvement in self-reported and
observer rated depression over 8 weeks, although there were no group differences. In contrast,
Rees et al. published a negative but properly executed trial on the use of omega-3 fatty acids in
a double blind, placebo-controlled trial (A23). Su et al. concluded the superiority of omega-3
fatty acids and showed that the intervention group had significantly lower mean HDRS scores
(MD = -4.70, 95%CI:-7.82 to -1.58) after 8 weeks of treatment (A26). At the trial endpoint, pa-
tients in the omega-3 group also had lower depressive symptom ratings on the EPDS and BDI.
Integrative collaborative care (ICC). Multidisciplinary care and personalized care have
received a lot of attention. Melville et al. evaluated their ICC in a RCT at an obstetric outpa-
tient clinic which included an engagement session, an assessment by a Depression Care man-
ager and potentially supported by antidepressant medication or problem-solving therapy for
primary care for 1 to 4 weeks (A18). After one year, the intervention group had significant
greater decrease of depressive symptoms on the Hopkins Symptom Checklist-20 compared to
the usual care group.
Anxiety disorders
Only one trial fulfilled the inclusion criteria for the treatment of anxiety disorders in pregnant
women. This trial included patients that met criteria for anxiety disorder or blood- and injec-
tion phobia according to DSM-IV criteria. The sample size of the included trial was 76 patients
and evaluated CBT in an open trial (A15). Patients received two sessions of group-CBT and
were compared with 46 women diagnosed with blood- and injection phobia, but untreated.
CBT-treated women scored significantly lower after each session and postpartum on anxiety
and avoidance scores.
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Methodological quality of trials and risk of bias
Data available for the meta-analysis was provided by 25 trials and methodological quality was
reported in a risk of bias table in the appendices. Twelve trials did not describe the procedure
of concealment of allocation and randomization. Blinding of the participants was not always
feasible, but in twelve trials participants or assessors were blinded. Attrition rates varied from
0 to 52%. Majority (72%) of the trials did not publish a protocol and/or was registered in a trial
register. Inter-rater agreement with regards to the quality assessment was substantial (raw
inter-rater agreement = 83%; κ = 0.70).
A visual inspection of the funnel plot revealed that the plot was symmetric, so we had no
indication of a publication bias (see Fig 2). Only three studies were identified outside the
pseudo 95% confidence interval (A10,A12,A24). Also, the Egger’s test did not suggest the pres-
ence of publication bias (β = 0.08; 95%CI:-0.83 to 0.99; p = 0.86).
Meta-analysis
For the patients with depression, we grouped the available interventions together in 1) CBT; 2)
IPT; 3) bright light therapy; 4) body-oriented therapies; 5) acupuncture; and 6) food supple-
ments (see Fig 3). No overall statistics were calculated for Integrating Collaborative Care
Fig 2. Funnel plot including pseudo 95% confidence limits of the included trials (k = 25) stratified by
intervention.
https://doi.org/10.1371/journal.pone.0173397.g002
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(k = 1) and a trial focussing on patients diagnosed with an anxiety disorder (k = 1). For
each intervention subgroup, we compared all available trials on improvement of psychiatric
symptoms and study quality as reported in S1 Table. Analysed in a random effect model,
the psycho-therapeutically interventions were both associated with reduction of depressive
symptoms. In case of CBT, treatment size was medium with little inconsistency between trials
(g = -0.61; 95%CI:-0.73 to -0.49), and overall effect was significant (Z-value = 10.04; p<0.001).
Among the 7 trials evaluating CBT, there was no evidence of heterogeneity (Tau2<0.001;
Chi2(6) = 2.72; p = 0.84; I2<1%). In case of IPT the effect was also medium. However, the mag-
nitude of the imprecision shows large inconsistencies between the trials (g = -0.67; 95%CI:-
1.27 to -0.07). Inconsistency among the four IPT trials was supported by the test for heteroge-
neity (Tau2 = 0.29; Chi2(3) = 14.01; p<0.001; I2 = 79%). Overall the treatment effect of IPT
was significant (Z-value = 2.20; p = 0.03). Overall treatment effect of bright light interventions
was not associated with a decrease of depressive symptoms (g = -0.59; 95%CI:-1.25 to 0.06;
I2 = 0%; Z-value = 0.77; p = 0.08). Heterogeneity was not tested significantly (Tau2<0.001;
Chi2(1) = .83; p = 0.36; I2<1%). Body-oriented intervention was associated with a medium
sized improvement, consistent over the trials (g = -0.43; 95%CI:-0.61 to -0.25), overall treat-
ment effect was significant (Z-value = 4.62; p<0.001). Heterogeneity was not tested signifi-
cantly (Tau2 = 0.02; Chi2(7) = 8.41; p = 0.30; I2 = 17%). Treatment with food supplements
was not associated with decrease of depressive symptoms (g = -0.51; 95%CI:-1.02 to -0.01;
Z-value = 1.92; p = 0.06). Heterogeneity was not tested significantly (Tau2 = 0.04; Chi2(2) =
2.49; p = 0.29; I2 = 20%). Finally, the two trials evaluating acupuncture showed a significant
medium overall treatment effect (g = -0.43; 95%CI:- 0.80 to 0.07; Z-value = 2.30; p = 0.02). Het-
erogeneity was not tested significantly (Tau2<0.001; Chi2(1) = 0.03; p = 0.86; I2<1%).
Sensitivity analysis. Fig 4 depicts the results from the sensitivity analyses. As the figure
shows, the overall treatment effect regarding symptoms of depression is robust to intervention
and trial characteristics and statistical method. The mode of intervention, i.e. group vs.
Fig 3. Hedges g of interventions to reduce depressive symptoms in pregnant women.
https://doi.org/10.1371/journal.pone.0173397.g003
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Fig 4. Intervention effect in the full set of included trials (k = 25) using fixed and random estimation,
and for different subgroups of trials. Pooled effect sizes for subgroups of trials are estimated using
random-effects estimation. Fixed-effect estimation was used to compare differences over subgroups.
https://doi.org/10.1371/journal.pone.0173397.g004
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individual therapy, nor any of the trial design characteristics, i.e. outcome measure, moment
of assessment, nor any of the trial quality characteristics showed a significant impact on the
overall intervention effect. Regression analysis revealed no significant association between
treatment effect and the age of the included patients (β = 0.01; 95% CI:-0.03 to 0.06, p = 0.69).
Discussion
Summary of evidence
The aim of this systematic review was to provide an overview of trials that evaluated pharma-
cological and non-pharmacological interventions for AMD and in addition to provide an esti-
mation of the overall effect size of categorized interventions per mental health outcome. Given
the importance of treating mental disorders during pregnancy for mother and child, this
meta-analysis extends the literature [29, 33, 34, 49] by thoroughly examine all available treat-
ments for AMD.
Until this date there are no controlled studies on the effect of psychotropic medication for
AMD. We could only estimate effect sizes for treatment of patients diagnosed with Major De-
pressive Disorder (MDD) by a lack of studies on other mental disorders during pregnancy. A
form of psychotherapy for MDD has robust effect sizes, e.g. Cognitive Behavioural Therapy
(CBT, g = -0.61), and to a lesser extent Interpersonal Psychotherapy (IPT, g = -0.67). Both may
hold potential benefit for pregnant women with MDD in this analysis. This is in line with current
NICE guideline that advises clinicians to offer a form of psychotherapy to every pregnant woman
with a history of mild to severe depression and emphasizes close consultation with patients [50].
Other potential beneficial non-pharmacological intervention categories to treat MDD were
body-oriented interventions and acupuncture. Our data suggests that bright light therapy is
not associated with a decrease of depressive symptoms, but this is based on two trials. Overall,
we identified only a small number of studies for each intervention category with small sample
sizes and potential risks of bias. We performed sensitivity analyses to evaluate the impact of
these moderator variables on the overall treatment effect, but none showed to be significant.
However, the ability to perform certain moderation analyses was limited by the size and qual-
ity of current English literature. In the majority of the trials only per protocol data was avail-
able and this has likely resulted in an overestimation of our effect sizes.
Our results showed that the overall effect sizes of all non-pharmacological intervention are
in close range to each other and may be redeemable for one other, bearing in mind the high
attrition rates of most trials. Furthermore, the effect sizes are similar or even higher than the
effect of psychotropic medication in non-pregnant depressed patients [51–53]. In summary,
the effect sizes of the different interventions to treat depressive symptoms are close to each
other and therefore we suggest that the preference of the patient have to weigh heavily in the
decision for a psychiatric treatment in a clinical setting.
Strengths and limitations
To our knowledge, a broad approach to examine various interventions for mental disorders
during pregnancy is not performed before. We limited our study to a clinical group of patients
with a diagnosed disorder, in order to extrapolate the evidence on treatment of AMDs for cli-
nicians. The disadvantage of this approach is that we missed potentially effective interventions
in a healthy population that could be beneficial also for a clinical sample. By pooling the inter-
ventions by six subgroups in our meta-analysis and conducting several sensitivity analyses, we
believe that we have been able to show the effects of each intervention and gained insight in
sources of variability between the included studies. Our estimates are lower than other meta-
analysis which report average effect for IPT, ranging between 1.14 (one-group studies) [33] to
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1.26 [29]. We focused only on the treatment period during pregnancy, on a clinical diagnosis
and controlled trials, therefore our results show a more robust estimate of the beneficial effect
of IPT for pregnant women with MDD. Post-hoc analysis of Claridge et al. focusing on high
quality clinical samples, found similar effect sizes (d = 0.40) [33].
We considered also open trials in our qualitative systematic review, because it is known that
this hard-to-reach population is difficult to enrol and randomize for trials, due to practical and
ethical reasons. As indicated by the funnel plot and Egger test, there was likely no publication
bias in this synthesis, and also our sensitivity analysis showed no potential biases. Altogether,
the advantage of our broad and systematic approach resulted in a comprehensive overview
and robust results.
Implications and conclusions
This meta-analysis contributes to the literature in several ways. Our review shows that the
number of trials on treatment of AMD is low, although rising every year. No controlled studies
were found to show evidence for the use of psychotropic medication during pregnancy. We
highlight the continuing need for further research of antepartum treatment for the full spec-
trum of AMDs, e.g. anxiety disorders, psychotic disorders, eating disorders, psychosomatic
disorder and comorbidity like personality disorders. The evidence provided is inconclusive,
and is predominantly based on trials evaluating major depressive disorder during pregnancy
in small sample sizes. It is recommended that future research include other mental disorders
in larger numbers and study alternative non-pharmacological interventions in comparison
with pharmacotherapy. Findings of alternative interventions offer the promise of efficacy
without the complexity of weighing pros and cons regarding foetal exposure to psychotropic
medication and maternal stress. For example body-oriented therapies (g = -0.43) and acupunc-
ture (g = -0.43) are promising alternatives, but the evidence is based on two to four trials and
the results should be replicated, preferably by researchers from different institutes. The re-
sults of omega-3 fatty acids intake are mixed and also a recent meta-analysis in non-pregnant
depressed patients suggests a small, non-significant benefit. However, nearly all of the treat-
ment efficacy might be attributable to publication bias [54]. Bright light therapy showed to be
effective for the treatment of non-seasonal depression in non-pregnant population [55], but
needs further research in pregnant women.
Our systematic review found also a high number of protocols, which are promising as well.
For example protocols for tapering antidepressants during pregnancy [56], for a broader range
of mood disorders [57–59] and a rise of mindfulness-based therapies is observed [60]. Due to
the small number of participants or weaknesses in design of the studies, we could not include
other alternative interventions that showed promising effect in case-series, e.g. Electrocon-
vulsive Therapy [61] and Transcranial Magnetic Stimulation [62, 63], or in healthy pregnant
women, e.g. exercise [64], music therapy [65] or multicomponent psychotherapy [66]. For
future research it would be interesting to examine the association between the severity of the
disorder with the improvement of psychiatric symptoms to further personalize treatments. It
should also be noted that the evidence was identified for short-term outcomes of AMD, and
that further research is needed to evaluate longer-term mother and child outcomes.
To conclude, in the field of perinatal psychiatry there is a lot of attention for depression and
a couple of evidence-based therapies are available and redeemable. However, the broader
range of mental disorder are not represented in current literature, while anxiety, bipolar and
other psychotic disorders may adversely affect mother and foetus, we strongly recommend fur-
ther research on both pharmacological and non-pharmacological treatment options for all
mental disorders during pregnancy.
Treatment of mental disorders during pregnancy
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